<DOC>
	<DOCNO>NCT02684162</DOCNO>
	<brief_summary>The goal clinical research study learn give donor lymphocyte cell SGI-110 help control acute myelogenous leukemia ( AML ) myelodysplastic syndrome ( MDS ) patient allogeneic stem cell transplant ( use someone else 's stem cell ) relapse . The safety treatment also study .</brief_summary>
	<brief_title>SGI-110 With Donor Lymphocyte Infusion ( DLI ) Acute Myelogenous Leukemia ( AML ) Myelodysplastic Syndrome ( MDS ) Relapsing Post Allogeneic Stem Cell Transplantation ( AlloSCT )</brief_title>
	<detailed_description>Study Treatment Administration : If find eligible take part study , receive SGI-110 injection skin 1 time day Days 1-5 28-day cycle . Day 1 first day receive study drug . If doctor think need , dose SGI-110 may change stop study . On Day 6 Cycles 2 , 4 , 6 , receive donor lymphocyte infusion vein 10-30 minute . Graft-versus-host disease ( GVHD ) may occur T-cell infusion . GVHD occur donor cell attack cell person receive stem cell transplant . If GVHD occur , give standard drug may help control GVHD . You may ask study staff information drug give risk . You continue receive study drug GVHD control . The study doctor discus . Study Visits : Within 3 day start cycle , Day 3 cycle , one time Weeks 2 3 cycle ( doctor think need ) , blood ( 2 tablespoon ) draw routine test check kidney liver function . Part blood sample used pregnancy test become pregnant . Urine may also collect pregnancy test . You may able blood draw perform local lab clinic closer home . The result test send study doctor MD Anderson review . Talk study doctor possibility . On Day 28 Cycles 1 , 2 , 4 , 6 : - Blood ( 2 tablespoon ) draw chimerism study , look see much blood cell mixed donor recipient . This test show well lymphocyte infusion `` take . '' - If doctor think need , may bone marrow aspiration biopsy perform check status disease . To collect bone marrow aspiration/biopsy , area hip numb anesthetic , small amount bone marrow bone withdrawn large needle . These tests/procedures may perform often , doctor think need . Length Treatment : You may receive 12 cycle SGI-110 . You may take study early disease get bad , intolerable side effect occur , develop uncontrolled severe GVHD , doctor think best interest . This investigational study . SGI-110 FDA approve commercially available . SGI-110 make decitabine , FDA approve commercially available treat MDS . SGI-110 currently use research purpose . The use donor lymphocytes treat MDS AML FDA approve . Up 50 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Diagnosis AML MDS accord WHO classification underwent first allogeneic HSCT either peripheral blood bone marrow source hematopoietic stem cell . 2 . Age 18 75 year old . 3 . No 1 antigen mismatch HLAA , B , C , DRB1 DQB1 locus either relate unrelated donor . 4 . Relapse allogeneic stem cell transplantation define one following : Morphological relapse : MDS patient : Reappearance dysplastic change bone marrow , without increase bone marrow blast count , pathologically consistent myelodysplastic syndrome . AML patient : Bone marrow blast count &gt; /= 5 % . Persistence reappearance minimal residual disease flow cytometry cytogenetic molecular testing . 5 . ECOG performance status 0 , 1 , 2 . 6 . Serum creatinine &lt; /= 1.5 mg/dL creatinine clearance great equal 40 cc/min define CockcroftGault Equation* . Males ( mL/min ) : ( 140age ) *IBW ( kg ) / 72* ( serum creatinine ( mg/dl ) ) . Females ( mL/min ) : 0.85* ( 140age ) *IBW ( kg ) / 72* ( serum creatinine ( mg/dl ) ) . 7 . Serum bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) . 8 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; /= 2.5 x ULN . 9 . Alkaline phosphatase &lt; /= 2.5 x UL . 10 . Capable understanding investigational nature , potential risk benefit study , able provide valid inform consent . 11 . HIV negative HBsAg negative . 12 . Negative serum urine pregnancy test woman reproductive potential . 1 . Use antileukemic agent relapse document ( note use antileukemic agent give posttransplant maintenance therapy allow study , e.g. , subcutaneous oral 5Azacytidine FLT3 inhibitor maintenance ) . 2 . Bone marrow blast count &gt; 60 % . 3 . Active acute GVHD grade II high . 4 . Active chronic GVHD extensive . 5 . Concurrent use systemic immune suppressive calcineurin inhibitor sirolimus . 6 . Active uncontrolled systemic fungal , bacterial viral infection . 7 . Symptomatic uncontrolled arrhythmias . 8 . Significant active cardiac disease within previous 6 month , include : New York Hear Association ( NYHA ) class III IV congestive heart failure ; Unstable angina angina require surgical medical intervention , and/or ; Myocardial infarction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myeloproliferative Diseases</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Donor lymphocyte infusion</keyword>
	<keyword>DLI</keyword>
	<keyword>Allogeneic stem cell transplant</keyword>
	<keyword>Stem cell transplantation</keyword>
	<keyword>AlloSCT</keyword>
</DOC>